The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of tyrosine kinase inhibitor on renal function in patients with advanced renal cell cancer.
Fumiya Hongo
Honoraria - Bayer; Pfizer
Masakatsu Oishi
No relevant relationships to disclose
Takashi Ueda
No relevant relationships to disclose
Terukazu Nakamura
No relevant relationships to disclose
Hiroyuki Nakanishi
No relevant relationships to disclose
Yoshio Naya
No relevant relationships to disclose
Kazumi Kamoi
No relevant relationships to disclose
Koji Okihara
No relevant relationships to disclose
Tsuneharu Miki
Honoraria - Bayer; Pfizer
Research Funding - Bayer; Pfizer